Atlas Venture Buys Stake in Biotech Firm ImageneBio

Investment firm takes 9.43% position in clinical-stage biotech company

Mar. 14, 2026 at 7:06am

Got story updates? Submit your updates here. ›

Atlas Venture Life Science Advisors LLC bought a new position in shares of ImageneBio, Inc. (NASDAQ:IMA) during the 3rd quarter, acquiring 377,814 shares valued at approximately $3.08 million. This represents a 9.43% stake in the clinical-stage biotechnology company, which is developing therapeutics for immunological and inflammatory diseases.

Why it matters

The investment by Atlas Venture, a prominent life sciences-focused venture capital firm, signals confidence in ImageneBio's pipeline and potential. As a major shareholder, Atlas Venture will likely play an active role in guiding the company's strategic direction and development of its lead product IMG-007, an anti-OX40 monoclonal antibody currently in Phase 2a trials for atopic dermatitis and alopecia areata.

The details

According to ImageneBio's latest SEC filings, the company had a market capitalization of $66.07 million as of its most recent quarter. The stock has traded between $5.70 and $18.00 over the past 52 weeks, closing at $5.91 on Friday. Several other institutional investors, including Goldman Sachs, Aldebaran Capital, BML Capital Management, and Vanguard Group, have also taken positions in ImageneBio in recent quarters.

  • Atlas Venture acquired the 377,814 shares of ImageneBio during the 3rd quarter of 2025.
  • ImageneBio's lead product IMG-007 has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata.

The players

Atlas Venture Life Science Advisors LLC

A prominent venture capital firm focused on investing in life sciences companies.

ImageneBio, Inc.

A clinical-stage biotechnology company developing therapeutics for immunological and inflammatory diseases, headquartered in San Diego, California.

Got photos? Submit your photos here. ›

The takeaway

The investment by Atlas Venture underscores the potential of ImageneBio's pipeline and the growing interest in the biotech sector from institutional investors. As ImageneBio advances its lead candidate IMG-007 through late-stage trials, the company's performance and strategic direction will be closely watched by the market.